Samsung Biologics Co., Ltd.

About Samsung Biologics Co., Ltd.


Samsung Biologics is a fully integrated CDMO partner providing highly tailored solutions to each client. Our end-to-end services include upstream and downstream process development, clinical and commercial manufacturing, aseptic fill/finish, and analytical and biosafety testing—all from a single location. Our plants are cGMP compliant holding 364KL total capacity with wide range of 1KL, 5KL, 15KL scale bioreactors. To meet the growing market demand, we are currently expanding manufacturing capacity with the new plant 4 with additional 264KL. 

- Virtual Exhibition Hall https://exhibition.samsungbiologics.com/#node1
- Plant 4 https://samsungbiologics.com/plant4/kr/

- Download corporate brochure to learn more about our service offerings https://samsungbiologics.com/media/pr-materials?tab=1

Samsung Biologics Co., Ltd. Industry Content
  • KR
  • 2018
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Contract Service
Contact info
Meet us at

CPHI Frankfurt 2022

Messe Frankfurt, Frankfurt, Germany
1-3 November 2022

Products from Samsung Biologics Co., Ltd. (3)

  • New plant, Plant 4

    Product New plant, Plant 4

    To fulfill the increasing demand of life-saving solutions for patients' lives all over the world, we decided to drive forward with building our new facility, Plant 4. Our accumulated expertise is implemented with the latest technologies and innovation, so that Plant 4 will be able to serve as part of your glo...
  • S-Cellerate™ to BLA

    Product S-Cellerate™ to BLA

    As biologics in development get closer to commercialization, drug developers are expected to implement rigorous process control measures to avoid potential manufacturing inconsistencies. A thorough understanding of process parameters and their potential impact on the product quality attributes and safety prof...
  • S-Cellerate™ to IND

    Product S-Cellerate™ to IND

    Speed to market is becoming increasingly crucial for commercial success. Enhanced timelines, which quickly advance the platform product to proof-of-concept (PoC) and first-in-human (FiH) studies, are already the new norm. Samsung Biologics’ S-Cellerate™ represents the faster path to IND, achieved through care...

Samsung Biologics Co., Ltd. Resources (19)